Doxycycline For Emphysema In People Living With Hiv (The Depth Trial)
Posted Date: Feb 16, 2023
- Investigator: Carl Fichtenbaum
- Specialties: AIDS-HIV, Pulmonary Diseases
- Type of Study: Drug
The prevalence of emphysema is higher in people living with HIV (PLWH) compared to controls without HIV, and progression may be accelerated. PLWH with early emphysema have increased alveolar macrophage gene expression of matrix metalloproteinase genes as well as MMP protein levels in bronchoalveolar lavage (BAL) fluid samples to an even greater extent than in HIV-negative individuals with emphysema. MMPs are therefore potential targets for intervention aimed at modifying the natural history of emphysema specifically in PLWH. We hypothesize that doxycycline, an MMP inhibitor, will reduce progression of emphysema in PLWH. This study is a phase II, multicenter, randomized, double-blinded, placebo-controlled clinical trial of 100 mg doxycycline BID for 72 weeks for emphysema in people living with HIV.
Criteria:
Individuals Age 30 Years And Older With Hiv-1 Infection Who Are Current Or Former Cigarette Smokers With Evidence Of Emphysema On High Resolution Ct (Hrct) Of The Chest.
Keywords:
Hiv, Emphysema, Doxycycline
For More Information:
Michelle Saemann
513-584-2245
saemanmd@ucmail.uc.edu